A newly developed assessment method that brings together a blood-based measurement and a physical body metric is showing promise for forecasting both survival chances and nutritional health in patients battling…
Dewpoint Therapeutics, a U.S.-based biotechnology innovator, has announced the successful closure of its Series D financing round. As reported by thepharmaletter, Dewpoint Therapeutics is renowned for its pioneering work in…
Editor's Note: Patient Worthy is proud to share this story from our friends at No Stomach for Cancer. To see the article in its original form, please click here. In…
Acknowledgment: This story is sponsored by Astellas Pharma US Inc. and is promoted through the Patient Worthy Collaborative Content program. We only publish content that embodies our mission of providing…
Researchers in Japan have developed a personalized mRNA vaccine that shows promise for treating recurrent gastric cancer, specifically peritoneal metastasis, which is often difficult to manage with existing therapies. This…
It seems that Summit Therapeutic’s $500 million investment in exchange for rights to Akeso may have paid off. According to a recent article in Fierce Biotech, an interim study gave…
Arcus Biosciences and Gilead Sciences issued a press release announcing encouraging overall response rates and six-month progression-free survival rate for their combination treatment of domvanalimab plus zimberelimab and chemotherapy…
November is Gastric Cancer Awareness Month. So what do you know about gastric cancer? Stomach cancer, or gastric cancer, is a cancer that manifests in the stomach lining. It often…
Editor's Note: We believe that patients are a key part of developing and leading the conversation in disease communities. Patient Worthy sometimes partners with reputable agencies that wish to speak…
Historically, it has been challenging to mobilize drug development and research within the rare disease sphere. Given the smaller community sizes, as well as a general lack of profitability,…
If gastric cancer is localized (has not yet spread), it carries a significantly higher 5-year survival rate of 72-75%. But once the cancer spreads, the rate falls lower: 35%…
According to a story from Healio, a phase 3 clinical trial evaluating pembrolizumab plus perioperative chemotherapy as a treatment for locally advanced and resectable gastric adenocarcinoma and gastroesophageal junction cancer…
Throughout the world, it can be difficult to advance research and drug development in the rare disease space. In part, this is because many rare diseases have small population…
There have been rising incidences of gastric cancer on a global scale. As a result, this cancer is now considered the fourth leading oncological cause of death worldwide. Gastric cancer…
SOTIO Biotech has just announced that the first patient has received the first dose of treatment in their Phase 1/2 trial for SOT102. SOT102 is an investigative treatment for pancreatic…
Unintended weight loss is a symptom associated with many different forms of cancer. But what can this weight loss tell researchers about the patients and their outcomes? Healio shares a…
Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…
Healio recently published results of the CheckMate 649 study confirming the benefits of combining nivolumab and chemotherapy in treating newly diagnosed patients with gastroesophageal junction cancer and advanced gastric and…
Platinum-based chemotherapy has been the standard treatment for patients with metastatic gastric adenocarcinoma for over ten years. According to a recent article in Healio, the median survival is about nine…
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
